C-reactive protein (CRP) 3 is a major human acute phase reactant composed of five identical subunits (1, 2). Accumulating evidence demonstrates that the actions of CRP depend on conformation and localization (3-5). CRP is primarily produced by the liver and circulates in the blood as a pentamer but is induced to dissociate into subunits (monomeric CRP, mCRP) upon interaction with the microenvironment at inflammatory loci (6 -18). mCRP exhibits markedly enhanced activities and recognizes an expanded list of binding partners. Following reduction of the intra-subunit disulfide bond, mCRP can be further activated (19). The degradation of mCRP, on the other hand, would generate bioactive fragments showing anti-inflammatory actions (20 -23). The differential contributions of these CRP conformations at distinct locations may therefore account for the intense controversies regarding the function of CRP in animal models and in clinical studies (3-5). mCRP appears to be the major conformation of CRP that regulates local inflammation (3-5), yet how it acts remains incompletely understood. In particular, though the markedly enhanced binding capability of mCRP underlies its actions, little is known through which sites mCRP recognizes diverse ligands. Consequently, no means is available to specifically modulate the actions of mCRP, which is necessary for clarifying the exact contributions of different CRP conformations in vitro and in vivo. The current study was designed to identify the recognition site of mCRP for ligand binding. The results unexpectedly demonstrated cholesterol binding sequence (CBS) as a versatile motif that mediates the interactions of mCRP with different types of ligands, including two newly identified herein. We further showed that synthetic CBS peptide was able to inhibit the proinflammatory actions of mCRP both in vitro and in vivo. Hence, optimized CBS peptide may be developed as a potential inhibitor of mCRP.
Experimental ProceduresReagents-Human native CRP (purity Ͼ 99%) purified from ascites was purchased from the BindingSite (Birmingham, UK; catalogue number: BP300.X). mCRP and acylated Cys-mutated mCRP was prepared as described (19,24). Proteins were dialyzed to remove NaN 3 , and passed through Detoxi-Gel Columns (Thermo Fisher Scientific, Rockford, IL; catalogue number: 20344) to remove endotoxin when necessary. CRP peptides (purity Ͼ 98%) were synthesized by Science Peptide Biological Technology (Shanghai, China). Lyophilized peptides were reconstituted aseptically with DMSO at 40 mg/ml and stored at Ϫ20°C in aliquots or kept at 4°C for a maximum of 1 week.